Skip to content

US · SLN · BIOTECHNOLOGY

Silence Therapeutics plc (SLN) intrinsic value and stock valuation

$19.81as of 2026-11-21 · Mkt cap 564.45M

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Silence Therapeutics plc DCF and intrinsic value

InvestorsCraft values SLN with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from SLN’s statements →

Silence Therapeutics plc Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology London, GL W14 8TH silence-therapeutics.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$560K-36.6% 5y CAGRd
20112025
Net income
-$-88.61M
20112025
Free cash flow
-$-62.33M
20112025
Total equity
$62.3M+47.1% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$560K$43.3M$25.4M$17.7M$12.4M
Operating income-$-89.75M-$-63.32M-$-49.6M-$-49.76M-$-45.81M
Net income-$-88.61M-$-45.31M-$-43.27M-$-41.03M-$-39.41M
EPSd-$-1.88M-$-2.94M-$-3.5M-$-3.82M-$-1.33M
Operating cash flow-$-62.27M-$-54.05M-$-39.35M-$-57.04M$9.19M
Capital expenditure-$-60K-$-170K-$-40K-$-550K-$-1.8M
Free cash flow-$-62.33M-$-54.22M-$-39.4M-$-57.59M$7.39M
Total assets$131.4M$161.9M$119.5M$107.5M$96.2M
Total debt$160K$90K$350K$450K$140K
Net debt-$-11.12M-$-96.86M-$-68.44M-$-54.37M-$-73.4M
Total equity$62.3M$107.1M$22M$22.1M$8.53M
Cash and short-term investments$85.1M$117.7M$68.8M$71.1M$73.5M
Income statement
20252024202320222021
Revenue$560K$43.3M$25.4M$17.7M$12.4M
Cost of revenue$210K$11.8M$10.3M$11M$7.46M
Gross profit$340K$31.5M$15.1M$6.68M$4.96M
Research and development expenses$67.8M$67.9M$44M$35.5M$30.8M
Selling, general and administrative expenses$22.3M$26.9M$20.6M$20.9M$20M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$90.1M$94.8M$64.7M$56.4M$50.8M
Cost and expenses$90.3M$106.6M$75M$67.4M$58.2M
Interest income$3.48M$4.47M$1.45M$230K$10K
Interest expense$0.00$0.00$30K$50K$10K
Depreciation and amortization$560K$590K$500K$490K$430K
Ebitda-$-88.05M-$-48.99M-$-49.78M-$-39.94M-$-45.42M
Operating income-$-89.75M-$-63.32M-$-49.6M-$-49.76M-$-45.81M
Total other income/expenses, net$1.15M$18.9M-$-710K$9.29M-$-40K
Income before tax-$-88.6M-$-44.46M-$-50.31M-$-40.47M-$-45.86M
Income tax expense$10K$840K-$-7.04M$560K-$-6.45M
Net income-$-88.61M-$-45.31M-$-43.27M-$-41.03M-$-39.41M
Weighted average shares outstanding$47.2M$15.4M$12.4M$10.7M$29.7M
Weighted average diluted shares outstanding$47.2M$15.4M$12.4M$10.7M$29.7M
Balance sheet
20252024202320222021
Cash and short-term investments$85.1M$117.7M$68.8M$71.1M$73.5M
Net receivables$24.6M$21.5M$24M$920K$330K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$118.7M$149.7M$103.2M$96.7M$86.3M
Property, plant and equipment, net$1.75M$1.58M$2.31M$2.2M$1.94M
Goodwill and intangible assets$10.9M$7.75M$10.3M$8.33M$7.62M
Long-term investments$0.00$0.00$0.00$280K$300K
Total non-current assets$12.8M$12.2M$16.3M$10.8M$9.86M
Total assets$131.4M$161.9M$119.5M$107.5M$96.2M
Accounts payable$4.41M$2.95M$3.35M$3.19M$4.07M
Short-term debt$90K$90K$460K$450K$140K
Deferred revenue$170K$240K$6.57M$0.00$0.00
Total current liabilities$13.6M$13.4M$22.3M$21.9M$15.2M
Long-term debt$70K$0.00$120K$0.00$0.00
Deferred revenue, non-current$55.5M$41.4M$75M$0.00$0.00
Total non-current liabilities$55.5M$41.4M$75.1M$63.5M$72.5M
Capital lease obligations$160K$90K$350K$450K$140K
Total liabilities$69.1M$54.8M$97.5M$85.4M$87.7M
Common stock$10.3M$8.22M$8.85M$5.39M$4.49M
Retained earnings-$-562.57M-$-378.8M-$-431.89M-$-263.26M-$-222.97M
Accumulated other comprehensive income (loss)-$-2.98M-$-9.41M$40.4M$53.3M$42.7M
Total equity$62.3M$107.1M$22M$22.1M$8.53M
Total investments$73.8M$20.8M$0.00$16.6M$300K
Total debt$160K$90K$350K$450K$140K
Net debt-$-11.12M-$-96.86M-$-68.44M-$-54.37M-$-73.4M
Cash flow statement
20252024202320222021
Net income-$-88.61M-$-28.92M-$-50.31M-$-50.33M-$-61.89M
Depreciation and amortization$560K$470K$500K$600K$580K
Stock-based compensation$8.07M$10.4M$13.1M$12.7M$11.7M
Change in working capital$10.2M-$-26.39M-$-11.66M-$-19.4M$52.4M
Accounts receivable$5.07M-$-720K$310K-$-10.54M$37.1M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00$0.00$0.00$0.00
Net cash provided by operating activities-$-62.27M-$-54.05M-$-39.35M-$-57.04M$9.19M
Investments in property, plant and equipment-$-60K-$-170K-$-40K-$-170K-$-1.77M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-47.99M-$-17.55M$16.4M-$-20.5M$11.7M
Common stock issued$10K$113.5M$25.3M$52.6M$41.7M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$10K$113.5M$25.2M$52.6M$41.5M
Net change in cash-$-110.05M$42M-$-790K-$-33.08M$62.2M
Cash at end of period$11.3M$97M$54M$66.3M$99.3M
Operating cash flow-$-62.27M-$-54.05M-$-39.35M-$-57.04M$9.19M
Capital expenditure-$-60K-$-170K-$-40K-$-550K-$-1.8M
Free cash flow-$-62.33M-$-54.22M-$-39.4M-$-57.59M$7.39M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Silence Therapeutics plc

        Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various rare and metabolic conditions. Central to their innovative approach is the mRNAi GalNAc Oligonucleotide Discovery platform, which is designed for precise targeting of specific disease-causing genes within the liver. The company's methodology harnesses the body's natural RNA interference (RNAi) mechanism by designing short interfering RNA (siRNA) molecules that degrade messenger RNA (mRNA), thereby preventing the production of targeted disease-associated proteins. Their pipeline features several promising candidates, including SLN360, currently in Phase I clinical trials for cardiovascular disease associated with elevated lipoprotein. Another key candidate, SLN124, is undergoing Phase I clinical trials for non-transfusion-dependent thalassemia and myelodysplastic syndrome, with further development planned for polycythemia vera. Silence Therapeutics also engages in strategic collaborations to expand its reach. It has agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for cardiovascular, renal, metabolic, and respiratory diseases. Furthermore, a partnership with Mallinckrodt Pharma IP Trading DAC aims to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company is also collaborating with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three unspecified targets, utilizing Silence's mRNAi GOLD platform. Originally incorporated as SR Pharma plc, the company rebranded to Silence Therapeutics plc in May 2007.

        CEO
        Iain Gladstone Ross
        Employees
        88
        Beta
        1.34

        Explore

        Frequently asked questions

        What is the intrinsic value of Silence Therapeutics plc (SLN)?

        Silence Therapeutics plc (SLN) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is SLN undervalued?

        SLN trades at a price of $19.81 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.